Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
57.7% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
27
users have liked this narrative
8
users have commented on this narrative
76
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
28.0% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
35
users have liked this narrative
7
users have commented on this narrative
97
users have followed this narrative
Updated
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
20.6% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
FARO Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Refreshing Core Offerings And Forming Partnerships Will Open New Markets
Key Takeaways FARO Technologies aims to drive revenue growth through refreshed solutions, new products, and strategic partnerships to expand market access and customer share. Continuous operational improvements are enhancing margins, contributing to operating leverage, and supporting earnings growth over time.
View narrative
US$44.00
FV
0.02% undervalued
intrinsic discount
3.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
19 days ago
author updated this narrative
FD Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
KX Focus And Cloud Partnerships Will Shape Future Success
Key Takeaways The divestment strategy and focus on KX aim to enhance growth through strategic partnerships and targeted market segments, potentially boosting revenue and profitability. Reducing cash burn and prioritizing profitability, alongside efficient resource use and shareholder capital returns, could improve margins and attract further investment.
View narrative
UK£24.50
FV
0% overvalued
intrinsic discount
15.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
19 days ago
author updated this narrative
Enviri
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
IT Upgrades And Order Completions Will Improve Efficiency In 2025
Key Takeaways Clean Earth's enhanced volume growth and common IT platform are projected to significantly improve EBITDA, impacting revenue and profit margins positively. Improvements and strategic spending in various segments are set to boost free cash flow and efficiency, positively affecting earnings and net margins.
View narrative
US$14.83
FV
41.7% undervalued
intrinsic discount
2.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
19 days ago
author updated this narrative
Prothena
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Key Takeaways Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities. Strategic partnerships and a strong financial position support pipeline advancement and potential long-term earnings growth.
View narrative
US$24.29
FV
68.3% undervalued
intrinsic discount
14.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
19 days ago
author updated this narrative
E2open Parent Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Client Retention And AI Integration Will Strengthen Future Position
Key Takeaways E2open's focus on client retention and AI integration is boosting revenue growth and client satisfaction. Investment in AI and trade solutions positions E2open to capitalize on market demands and strong earnings potential.
View narrative
US$3.30
FV
0% overvalued
intrinsic discount
1.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
19 days ago
author updated this narrative
Real Brokerage
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Leo CoPilot And Fintech Ecosystem Will Improve Client Experiences
Key Takeaways Expansion of the consumer-facing ecosystem and financial products is expected to streamline experiences and enhance profit margins through efficient service attachment. Strategic scaling of services like mortgages and titles and adjustments to fees aim to boost profit margins and improve long-term profitability.
View narrative
US$6.33
FV
37.8% undervalued
intrinsic discount
21.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
19 days ago
author updated this narrative
DWL
Dowlais Group
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Powertrain Model Shift And Restructuring Will Boost Operational Efficiency
Key Takeaways Strategic shift to a powertrain-agnostic model and regional focus is aimed at enhancing business resilience and efficiency, boosting future net margins. Diversification into new growth areas like metal additive manufacturing and LFP batteries is expected to drive revenue growth and market stability.
View narrative
UK£0.70
FV
8.4% overvalued
intrinsic discount
-0.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
19 days ago
author updated this narrative
Curaleaf Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Premium Flower And European Medical Programs Will Create Future Opportunities
Key Takeaways Strategic initiatives like the ROOTS program and operational efficiencies aim to enhance margins and strengthen financial health. International expansion, new products, and premium offerings are poised to drive revenue growth and bolster market presence.
View narrative
CA$3.72
FV
24.7% undervalued
intrinsic discount
3.87%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
19 days ago
author updated this narrative
CareDx
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
Key Takeaways Expanding transplant procedures and adoption of precision diagnostics drive sustainable revenue growth and strengthen CareDx’s competitive positioning. Strategic investments in digital health and robust evidence generation enhance operational efficiency, recurring high-margin revenues, and payer reimbursement opportunities.
View narrative
US$27.50
FV
56.5% undervalued
intrinsic discount
10.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
19 days ago
author updated this narrative
Value any company in seconds
Popular companies